Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 July 1995 | Volume 123 Issue 2 | Pages 110-113
Objective: To determine if nitric oxide output in exhaled air is increased in patients with liver cirrhosis.
Design: Cross-sectional study.
Setting: A university hospital.
Patients: 50 patients with liver cirrhosis, 6 patients with chronic hepatitis, and 15 healthy controls.
Measurements: Nitric oxide in exhaled air was measured using a chemiluminescence analyzer. Cardiac index was determined using echocardiography.
Results: Patients with decompensated liver cirrhosis had higher levels of exhaled nitric oxide output (Child C patients, 190 ±11 nL/min per m2 body surface area) than controls (97 ±8 nL/min per m2 body surface area; P < 0.001), whereas patients with compensated liver cirrhosis or chronic hepatitis had levels of nitric oxide output similar to those found in controls. Cardiac index was greater in patients with liver cirrhosis (Child C patients, 4.3 ±0.3 L/min per m2 body surface area) than in controls (2.9 ±0.2 L/min per m2 body surface area; P < 0.001). Cardiac index correlated with nitric oxide levels (r = 0.621; P < 0.001).
Conclusions: Increased nitric oxide output in exhaled air is associated with systemic circulatory disturbances in patients with liver cirrhosis.
Fifty-six patients were consecutively selected from those hospitalized in our department. All had biopsy-proven chronic hepatitis or liver cirrhosis; none had primary lung disease, hypertension, or infection. They could walk in the ward unaided and did not need intensive care. Physical examination findings and blood data were analyzed to classify hepatocellular function in liver cirrhosis according to the Child criteria. The clinical background of these patients is summarized in Table 1. Healthy volunteers served as controls (15 men; 34 ±2 years of age; body surface area, 1.84 ±0.03 m2). All medications were discontinued 24 hours before each study began. No antihypertensives or vasodilators, including nitrates and angiotensin-converting enzyme inhibitors, were used in these patients. The study was approved by the hospital ethics committee, and informed consent was obtained from each study participant. BRIEF COMMUNICATION
Increased Nitric Oxide in the Exhaled Air of Patients with Decompensated Liver Cirrhosis
Patients with liver cirrhosis often present with several systemic hemodynamic disturbances, including hypotension, low systemic vascular resistance, and a reduced sensitivity to vasoconstrictors [1]. As cirrhosis progresses, vascular resistance continues to decrease, and the low arterial pressure may lead to secondary disturbances in renal and hepatic blood flow and to ascites [1]. The precise mechanisms of these hemodynamic disorders have not yet been clearly elucidated. Excessive production of vasodilators, such as prostacyclin, bradykinin, substance P, and atrial natriuretic peptide, has been proposed, but there is no clear evidence to show that vasodilators are involved. Vallance and Moncada [2] hypothesized that nitric oxide, originally discovered as an endothelium-derived relaxing factor [3], may be a causative factor in hemodynamic disorders in patients with liver cirrhosis. High concentrations of circulating endotoxin are frequently found in patients with cirrhosis who have no clinical evidence of infection [4]. Thus, the endotoxemia of liver cirrhosis may induce nitric oxide synthase directly in blood vessels or indirectly through cytokines, leading to an increased synthesis and release of nitric oxide that may account for the hemodynamic abnormalities. Recent studies show that nitric oxide concentration in exhaled air can be measured [5-7] and that it is increased in patients with bronchial asthma [5, 6]. To test the hypothesis that an increased synthesis and release of nitric oxide accounts for hemodynamic abnormalities in patients with liver cirrhosis, we investigated whether nitric oxide output in exhaled air is increased in these patients.
Methods
![]()
Top
Methods
Results
Discussion
Author & Article Info
References
Patients
|
Nitric Oxide Measurement
The nitric oxide concentration in exhaled air was determined at least 3 hours after meals while each participant was at rest in the sitting position, as previously described [7]. Each participant was asked to inhale synthetic air (Taiyo Sanso Co., Osaka, Japan) free of nitric oxide (< 3 parts per billion [ppb]) through a mask and a T-valve, and to exhale the air into a wide-bore Teflon tube (internal diameter, 25 mm; length, 600 mm). Exhaled air was continuously drawn from this tube with a vacuum pump and was introduced into a chemiluminescence analyzer (APNE-350E, Horiba Co., Kyoto, Japan). Measurement of nitric oxide concentration was based on the reaction of nitric oxide with ozone. The sensitivity of the analyzer to nitric oxide ranged from 2 to 1000 ppb. The system was calibrated with dilutions of certified nitric oxide gas (450 ppb in nitrogen; Taiyo Sanso Co.) using mass flowmeters (Estec Co., Kyoto, Japan). Expired volume was measured with a hot-wire flow meter connected to the T-valve on the expiratory side, and minute ventilation was calculated using a breath-by-breath respirometer (RM-280, Minato Medical Science Co., Tokyo, Japan). The nitric oxide concentration and minute ventilation were recorded with a computer-assisted data recorder (DS1100, Fukuda Denshi Co., Tokyo, Japan), and the output of nitric oxide was calculated as follows: nitric oxide output = (nitric oxideex nitric oxidein) x minute ventilation/body surface area, where nitric oxideex was the nitric oxide concentration in exhaled air, and nitric oxidein was the nitric oxide concentration in inhaled air. Nitric oxide concentration and minute ventilation were monitored simultaneously for 10 minutes, and the data obtained during the last 3 minutes was averaged. During the study period, the ambient levels of nitric oxide concentration were less than 5 ppb. Nitric oxide output was reproducible in patients with cirrhosis and in controls (coefficient of variation, 10.8% [n = 5] for patients and 9.3% [n = 5] for controls) on separate days, and there was no significant time-course change in nitric oxide output at rest.
Echocardiographic Measurement
To examine the relation between systemic hemodynamics and nitric oxide production, we measured cardiac output using transthoracic two-dimensional echocardiography (SSD-2200, Aloka Co., Tokyo, Japan) in 19 patients with liver cirrhosis and in 6 controls. This was done on the same day that nitric oxide concentrations were measured. A physician, who was blinded to the patient characteristics and the exhaled nitric oxide output values, obtained echocardiographic views and recorded them on videotape. Another physician, who was also blinded to these data, measured cardiac output using the echocardiographic images. Left ventricular dimension was measured in the long-axis view of the left ventricle while the patient was in the left lateral decubitus position. Left ventricular volume and cardiac index were obtained by the following formulae according to the Teichholz equation [8]: left ventricular volume = 7.0 x dimension3/(2.4 + dimension); cardiac index = (left ventricular end-diastolic volume -end-systolic volume) x heart rate/body surface area. Blood pressure was measured with a sphygmomanometer. Total peripheral resistance index was calculated as mean blood pressure x 80/cardiac index. The cardiac index obtained by this method on separate days was reproducible in patients with cirrhosis and in controls (coefficient of variation, 9.1% [n = 6] in patients and 8.6% [n = 5] in controls).
Statistical Analysis
Values are expressed as the mean ±SE. Differences between patients and controls were compared using one-way analysis of variance (ANOVA) followed by the Fisher test. The correlation coefficient was calculated using the least-squares method. Statistical significance was set at P < 0.05.
Results
|
|---|
|
|
|---|
|
The results of hemodynamic measurements showed that patients with Child C liver cirrhosis had a greater cardiac index per m2 body surface area (4.3 ±0.3 L/min compared with 2.9 ±0.2 L/min; P < 0.001) and a smaller total peripheral resistance per m2 body surface area (1732 ±125 dyne/s x cm5 compared with 2680 ±235 dyne/s x cm5; P = 0.004) than controls. There was a positive correlation between the level of nitric oxide output and cardiac index (r = 0.621; P < 0.001) (Figure 2).
|
Discussion
|
|---|
|
|
|---|
, have been shown in patients with liver diseases [9, 10]. The liver may produce large amounts of nitric oxide in these patients: Hepatocytes and Kupffer cells are known to produce nitric oxide in vitro in response to lipopolysaccharide and several cytokines [11, 12]. The plasma levels of cytokines, including tumor necrosis factor, are much lower in patients with liver cirrhosis than in these in vitro studies [10-15]. However, in vitro studies have also shown that endotoxin and cytokines also induce nitric oxide synthase in other tissues, including vascular endothelium, smooth muscle, and bronchial epithelium [13-15]. Thus, it is possible that vascular and bronchial tissues in the lungs of patients with liver cirrhosis produce nitric oxide as a result of continuous stimulation by the lower concentrations of cytokines, because the plasma levels of cytokines in patients with cirrhosis are similar to those in normal persons who have become hypotensive through the administration of endotoxin [10, 16]. Because most nitric oxide is inactivated by hemoglobin or rapidly metabolized to nitrite and nitrate [3], nitric oxide in exhaled air may be the residual of excessive local production of nitric oxide by the lung rather than a product of the liver. Because plasma nitrite and nitrate levels reflect the sum of nitric oxide production in the entire body, including the liver, the significance of the increase in exhaled nitric oxide output may differ from that of the increased plasma concentrations of nitrite and nitrate in patients with cirrhosis [17]. We did not measure the plasma levels of endotoxin, cytokines, and nitrite and nitrate, but these levels have been reported to vary widely, even among patients with similar degrees of liver damage [10, 17]. This is compatible with our finding of a large spread within each group and a significant overlap among the groups in exhaled nitric oxide levels.
Increased production of nitric oxide in the lungs may exert a vasodilatory effect on the pulmonary circulation. It has been suggested that such increased production may play a significant role in patients with the hepatopulmonary syndrome, because the administration of methylene blue, an inhibitor of guanylate cyclase, restores hypoxia in these patients [18]. If other vascular beds behave in a similar way, induction of nitric oxide synthase in the whole body will result in the hyperdynamic state associated with the decrease in total peripheral resistance and the increase in total venous capacitance found in patients with cirrhosis [1]. In our study, patients with liver cirrhosis were in a hyperdynamic state that was associated with an increase in nitric oxide output. Although it is not necessarily true that the increase in nitric oxide caused the hyperdynamic state, previous experimental and human studies have suggested that nitric oxide may play such a causative role. Rats with cirrhosis have enhanced sensitivity to the pressor effect of nitric oxide inhibition, indicating that increased endogenous nitric oxide contributes to arterial hypotension [19]. In addition, hyporesponsiveness to pressor stimuli is reversed by the inhibition of nitric oxide in animal models of portal hypertension [20]. Thus, nitric oxide has been shown to play an important role in regulating the vasomotor tone in experimental liver cirrhosis. Furthermore, methylene blue reversed severe hypotension in a human patient with liver failure [21]. Taken together, these findings suggest that excessive production of nitric oxide may account for the hemodynamic abnormalities seen in patients with liver cirrhosis. The inhibition of nitric oxide synthesis might reverse these abnormalities, although the need for development of specific inhibitors of constitutive or inducible nitric oxide synthase remains.
Increased nitric oxide output in exhaled air is associated with systemic circulatory disturbances in patients with liver cirrhosis. Measurement of nitric oxide output in exhaled air is a noninvasive examination that may provide clues to understanding the hemodynamic disturbances seen in patients with liver cirrhosis.
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med. 1958; 24:358-67.
2. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991; 337:776-8.
3. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43:109-42.
4. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 1988; 8:232-6.
5. Persson MG, Zetterstrom O, Agrenius V, Ihre E, Gustafsson LE. Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet. 1994; 343:146-7.
6. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994; 343:133-5.
7. Matsumoto A, Hirata Y, Momomura S, Fujita H, Yao A, Sata M, et al. Increased nitric oxide production during exercise (Letter). Lancet. 1994; 343:849-50.
8. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol. 1976; 37:7-11.
9. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology. 1991; 13:267-76.
10. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992; 103:264-74.
11. Spitzer JA. Cytokine stimulation of nitric oxide formation and differential regulation in hepatocytes and nonparenchymal cells of endotoxemic rats. Hepatology. 1994; 19:217-28.
12. Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK, Di Silvio MD, Wang SC, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci U S A. 1993; 90:3491-5.
13. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett. 1990; 275:87-90.
14. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A. 1990; 87:10043-7.
15. Asano K, Chee CB, Gaston B, Lilly CM, Gerard C, Drazen JM, et al. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci U S A. 1994; 91:10089-93.
16. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989; 321:280-7.
17. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993; 18:1139-43.
18. Rolla G, Bucca C, Brussino L. Methylene blue in the hepatopulmonary syndrome (Letter). N Engl J Med. 1994; 331:1098.
19. Claria J, Jimenez W, Ros J, Asbert M, Castro A, Arroyo V, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology. 1992; 15:343-9.
20. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology. 1992; 16:1043-8.
21. Midgley S, Grant IS, Haynes WG, Webb DJ. Nitric oxide in liver failure (Letter). Lancet. 1991; 338:1590.
This article has been cited by other articles:
![]() |
J W Ferguson, A R Dover, S Chia, N L M Cruden, P C Hayes, and D E Newby Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites Gut, April 1, 2006; 55(4): 542 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Ratnawati and P S Thomas Exhaled nitric oxide in paediatric asthma Chronic Respiratory Disease, July 1, 2005; 2(3): 163 - 174. [Abstract] [PDF] |
||||
![]() |
R. Rodriguez-Roisin, M.J. Krowka, Ph. Herve, M.B. Fallon, and on behalf of the ERS Task Force Pulmonary-Hepatic Pulmonary-Hepatic vascular Disorders (PHD) Eur. Respir. J., November 1, 2004; 24(5): 861 - 880. [Full Text] [PDF] |
||||
![]() |
G. Rolla, L. Brussino, E. Scappaticci, M. Morello, R. Innarella, F. Rosina, and C. Bucca Source of Exhaled Nitric Oxide in Primary Biliary Cirrhosis Chest, November 1, 2004; 126(5): 1546 - 1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.T. Dinh-Xuan and R. Naeije The hepatopulmonary syndrome: NO way out? Eur. Respir. J., May 1, 2004; 23(5): 661 - 662. [Full Text] [PDF] |
||||
![]() |
S. Cook, P. Vollenweider, B. Menard, M. Egli, P. Nicod, and U. Scherrer Increased eNO and pulmonary iNOS expression in eNOS null mice Eur. Respir. J., May 1, 2003; 21(5): 770 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. HON, K. H. LEE, and H. E. KHOO Nitric Oxide in Liver Diseases: Friend, Foe, or Just Passerby? Ann. N.Y. Acad. Sci., May 1, 2002; 962(1): 275 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. DELCLAUX, B. MAHUT, F. ZERAH-LANCNER, C. DELACOURT, S. LAOUD, D. CHERQUI, C. DUVOUX, A. MALLAT, and A. HARF Increased Nitric Oxide Output from Alveolar Origin during Liver Cirrhosis versus Bronchial Source during Asthma Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 332 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. B. Perillo, R. W. Hyde, A. J. Olszowka, A. P. Pietropaoli, L. M. Frasier, A. Torres, P. T. Perkins, R. E. Forster II, M. J. Utell, and M. W. Frampton Chemiluminescent measurements of nitric oxide pulmonary diffusing capacity and alveolar production in humans J Appl Physiol, November 1, 2001; 91(5): 1931 - 1940. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Schenk, C. Madl, S. Rezaie-Majd, S. Lehr, and C. Muller Methylene Blue Improves the Hepatopulmonary Syndrome Ann Intern Med, November 7, 2000; 133(9): 701 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Teramoto, T. Ishii, Y. Ouchi, A. Chaouat, E. Weitzenblum, and R. Schott The Mechanism of Hypoxemia in Liver Disease With Pulmonary Hypertension Chest, February 1, 2000; 117(2): 614 - 615. [Full Text] [PDF] |
||||
![]() |
A. P. Pietropaoli, I. B. Perillo, A. Torres, P. T. Perkins, L. M. Frasier, M. J. Utell, M. W. Frampton, and R. W. Hyde Simultaneous measurement of nitric oxide production by conducting and alveolar airways of humans J Appl Physiol, October 1, 1999; 87(4): 1532 - 1542. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. SARTORI, M. LEPORI, T. BUSCH, H. DUPLAIN, W. HILDEBRANDT, P. BÄRTSCH, P. NICOD, K. J. FALKE, and U. SCHERRER Exhaled Nitric Oxide Does Not Provide a Marker of Vascular Endothelial Function in Healthy Humans Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 879 - 882. [Abstract] [Full Text] |
||||
![]() |
S. Teramoto, T. Matsuse, and Y. Ouchi Nitric Oxide and Impaired Oxygenation before and after Liver Transplantation Ann Intern Med, July 6, 1999; 131(1): 69 - 69. [Full Text] [PDF] |
||||
![]() |
A. B. DuBois, P. M. Kelley, J. S. Douglas, and V. Mohsenin Nitric oxide production and absorption in trachea, bronchi, bronchioles, and respiratory bronchioles of humans J Appl Physiol, January 1, 1999; 86(1): 159 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Geigel, R. W. Hyde, I. B. Perillo, A. Torres, P. T. Perkins, A. P. Pietropaoli, L. M. Frasier, M. W. Frampton, and M. J. Utell Rate of nitric oxide production by lower alveolar airways of human lungs J Appl Physiol, January 1, 1999; 86(1): 211 - 221. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-Y. Martin, P. Gines, and R. W. Schrier Nitric Oxide as a Mediator of Hemodynamic Abnormalities and Sodium and Water Retention in Cirrhosis N. Engl. J. Med., August 20, 1998; 339(8): 533 - 541. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||